About this Research Topic
Integrin αvβ3 is one of a family of structural heterodimeric proteins of the plasma membrane that interact with extracellular matrix proteins and are generously expressed by cancer cells and dividing endothelial cells. It is now known that receptor sites for nonpeptide hormones, such as thyroid hormone and steroids, exist on αvβ3 and nongenomically mediate actions of these hormones on cancer cell proliferation and on angiogenesis. These receptor sites share no structural homologies with nuclear receptors for nonpeptide hormones that mediate genomic actions. However, the αvβ3 receptors may modulate expression of specific genes relevant to cancer cell survival and may control from the cell surface the activating phosphorylation of nuclear hormone receptors.
For this issue of the journal, we will invite papers dealing with cancer- and angiogenesis-relevant actions at αvβ3 of thyroid hormone, thyroid hormone analogues and sex steroids, including a stilbenoid (resveratrol). Papers will also describe use of hormone receptor sites on αvβ3 to image cancers and describe chemically modified hormones with payload capabilities which target hormone receptor sites on αvβ3 for delivery of anticancer drugs.
For this issue of the journal, we will invite papers dealing with cancer- and angiogenesis-relevant actions at αvβ3 of thyroid hormone, thyroid hormone analogues and sex steroids, including a stilbenoid (resveratrol). Papers will also describe use of hormone receptor sites on αvβ3 to image cancers and describe chemically modified hormones with payload capabilities which target hormone receptor sites on αvβ3 for delivery of anticancer drugs.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
